Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
4532775
Reference Type
Technical Report
Title
Atypical opioid mechanisms of control of injury-induced cutaneous pain by delta receptors
Author(s)
Scherrer, G
Year
2018
Is Peer Reviewed?
No
Publisher
U.S. Army Medical Research and Materiel Command
Location
Fort Detrick, MD
Report Number
AD1063833
Number of Pages
23
Language
English
URL
https://apps.dtic.mil/sti/citations/AD1063833
Exit
Abstract
Severe pain due to war-related injuries is difficult to treat, and current opioids (i.e. mu opioid receptor agonists such as morphine) cause unacceptable side effects including addiction. Injuries suffered most frequently by active military personnel include traumatic brain injury, nerve trauma, skin incision, and burn injury, and all these injuries are associated with acute cutaneous pain and/or mechanical allodynia/hypersensitivity. The goals of our research are to evaluate analgesics acting on delta opioid receptors (DORs) in animal models relevant to todays battlefield experience (Specific Aim 2), and elucidate the mechanisms by which DOR agonists, administered in skin and acting on mechanosensory dorsal root ganglia neurons, relieve pain (Specific Aim 1). We have determined the analgesic effect of two DOR agonists, deltorphin II and SNC80. We show that these compounds significantly elevate mechanical pain threshold, indicating their acute antinociceptive action. Furthermore, we found that in two models of injuries, namely skin incision and nerve trauma, a single injection of deltorphin II eliminates the mechanical hyper sensitivity caused by injury. We have also initiated studies aiming at identifying the peripheral sensory neurons that express DOR, a first step towards understanding the analgesic mechanism of action of DOR agonists. We are currently extending these findings by performing the other experiments described in our original proposal, without significant change in our plans and strategy. Importantly, our promising results support our hypothesis that DOR agonists, acting in the skin, represents an effective therapeutic strategy for blocking severe pain associated with injuries that can be suffered on the battlefield.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity